AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive-behavioural therapy (TCBT)
Number of subjects: 558
Study 30971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered cognitive-behavioural therapy (WCBT)
Number of subjects: 558
Study 30971419 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study 29797592 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-based injury prevention program (IPP) administered 1 day post-match (MD+1)
Number of subjects: 18
Study 29797592 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-based injury prevention program (IPP) administered 3 days post-match (MD+3)
Number of subjects: 18
Study 27064798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stent post-dilated with a paclitaxel-coated balloon
Number of subjects: 32
Study 24887897 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 249
Study 24887897 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 249
Study 22808224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (BL: ≈ 4.420 lx)
Number of subjects: 43
Study 22808224 — intervention group
Group type: COMPARATOR
Intervention: Dim light (DL: ≈ 230 lx)
Number of subjects: 43
Study 19918047 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 microg/day
Number of subjects: 387
Study 19918047 — intervention group
Group type: COMPARATOR
Intervention: alendronate 10 mg/day
Number of subjects: 387
Study 16959916 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins E, A, and C for 2 months, allopurinol for 15 days, and N-acetylcysteine for 3 days)
Number of subjects: 32
Study 16959916 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 32
Study 16959916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15938591 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole pre-treatment for 3 days
Number of subjects: 12
Study 15938591 — intervention group
Group type: COMPARATOR
Intervention: Alginate tablets alone
Number of subjects: 12
Study 11984383 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) inhalation
Number of subjects: 0
Study 11984383 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-emetic treatment
Number of subjects: 0
Study 9523400 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 2200
Study 9523400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 2200
Study 9523400 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 2200
Study 9523400 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational protocol
Number of subjects: 2200
Study 9523400 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Number of subjects: 2200
Study 8588647 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 87
Study 8588647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 2691174 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201-995, 50 micrograms subcutaneously)
Number of subjects: 7
Study 2691174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 4270384 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 4270384 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 0
Study 31221117 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-led intervention
Number of subjects: 620
Study 29245361 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 120
Study 29245361 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Remifentanil
Number of subjects: 120
Study 29245361 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Midazolam-Remifentanil
Number of subjects: 120
Study 26046967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhIGF‐I/rhIGFBP‐3 (30 mg/d)
Number of subjects: 56
Study 26046967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhIGF‐I/rhIGFBP‐3 (60 mg/d)
Number of subjects: 56
Study 26046967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23446019 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (E-PRP) drops for 3 months
Number of subjects: 108
Study 23446019 — intervention group
Group type: COMPARATOR
Intervention: Balanced saline solution
Number of subjects: 108
Study 17129461 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline (200 mg/d) twice daily
Number of subjects: 110
Study 17129461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12581466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable subscription (one piece per day)
Number of subjects: 1493
Study 12581466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no subscription)
Number of subjects: 1493
Study 11112891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination (FP/Salm Combo) - FP 100 microg plus salmeterol 50 microg twice daily through the Diskus inhaler
Number of subjects: 447
Study 11112891 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate plus montelukast (FP + montelukast) - FP 100 microg twice daily plus oral montelukast 10 mg once daily
Number of subjects: 447
Study 8840374 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (mean rate 8.9 +/- 3.5 mg/minute, range 3.9-16.7 mg/minute)
Number of subjects: 44
Study 8840374 — intervention group
Group type: COMPARATOR
Intervention: Control antibiotics (ceftazidime, cefuroxime, cefotaxime, ceftriaxone, or ampicillin-sulbactam)
Number of subjects: 44
Study 1334524 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 mg daily with conjugated equine oestrogens 0.625 mg (CEE)
Number of subjects: 124
Study 1334524 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 mg daily with transdermal 17 beta‐oestradiol 0.05 mg (E2‐TTS)
Number of subjects: 124
Study 1334524 — intervention group
Group type: COMPARATOR
Intervention: Control group (87 postmenopausal women)
Number of subjects: 124
Study 6427533 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 200
Study 6427533 — intervention group
Group type: COMPARATOR
Intervention: 10-day multiple-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 200
Study 6427533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (single-dose and multiple-dose)
Number of subjects: 200
Study 30557693 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and/or zinc supplementation
Number of subjects: 602
Study 30557693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 602
Study 28072691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg plus aspirin 100 mg
Number of subjects: 200
Study 28072691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg plus aspirin 100 mg
Number of subjects: 200
Study 28072691 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 200
Study 25468004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session brief intervention with family support (BI-FS)
Number of subjects: 169
Study 25468004 — intervention group
Group type: COMPARATOR
Intervention: Single-session brief intervention (BI)
Number of subjects: 169
Study 23673251 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term media violence exposure
Number of subjects: 0
Study 23673251 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21749907 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (N=16)
Number of subjects: 30
Study 21749907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (N=14)
Number of subjects: 30
Study 21749907 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and Sertraline (combined)
Number of subjects: 30
Study 21749907 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=28)
Number of subjects: 30
Study 19969212 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRS implantation followed by CXL (Group 2)
Number of subjects: 0
Study 19969212 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL followed by ICRS implantation (Group 1)
Number of subjects: 0
Study 17589773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) supplementation
Number of subjects: 0
Study 17589773 — intervention group
Group type: COMPARATOR
Intervention: Iron only supplementation
Number of subjects: 0
Study 15249503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 459
Study 15249503 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 459
Study 15249503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in proximal LAD lesions
Number of subjects: 459
Study 15249503 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents in proximal LAD lesions
Number of subjects: 459
Study 11578883 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 2438
Study 11578883 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 2438
Study 9775925 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Reflexology (FR) for 15 minutes for 5 days
Number of subjects: 130
Study 9775925 — intervention group
Group type: COMPARATOR
Intervention: Foot/Leg Massage (FM) for 15 minutes for 5 days
Number of subjects: 130
Study 9775925 — intervention group
Group type: COMPARATOR
Intervention: Talking for 15 minutes for 5 days
Number of subjects: 130
Study 7848398 — intervention group
Group type: EXPERIMENTAL
Intervention: Argyle tracheal tube
Number of subjects: 90
Study 7848398 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex tracheal tube
Number of subjects: 90
Study 7848398 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendall Curity tracheal tube
Number of subjects: 90
Study 3071588 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg three times a day)
Number of subjects: 23
Study 3071588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg three times a day)
Number of subjects: 23
Study 3071588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29890864 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) as part of a multimodal cocktail injection
Number of subjects: 100
Study 29890864 — intervention group
Group type: COMPARATOR
Intervention: Multimodal cocktail injection without morphine (control group)
Number of subjects: 100
Study 29231438 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife treatment (Fengchi GB 20, infraoccipital ashi point), once every three days for 5 times as one course.
Number of subjects: 366
Study 29231438 — intervention group
Group type: COMPARATOR
Intervention: Massage treatment, once every two days for 7 times as one course.
Number of subjects: 366
Study 25906792 — intervention group
Group type: EXPERIMENTAL
Intervention: Film ending with protagonist's suicide
Number of subjects: 95
Study 25906792 — intervention group
Group type: EXPERIMENTAL
Intervention: Film featuring main character positively coping with crisis
Number of subjects: 95
Study 23047003 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study 23047003 — intervention group
Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study 21357811 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH VA intervention (6-month program with 12 individual in-home and telephone sessions and 5 telephone support group sessions)
Number of subjects: 0
Study 21357811 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH VA intervention
Number of subjects: 0
Study 19678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg/day
Number of subjects: 1032
Study 19678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg/day
Number of subjects: 1032
Study 19678713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study 16861404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 16861404 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 15309453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose soy protein product with added beta-sitosterol (10 g once daily)
Number of subjects: 36
Study 10831195 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl (BF)
Number of subjects: 60
Study 10831195 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-morphine (BM)
Number of subjects: 60
Study 9251504 — intervention group
Group type: EXPERIMENTAL
Intervention: Toborinone at 5 micrograms.kg‐1.min‐1
Number of subjects: 0
Study 9251504 — intervention group
Group type: EXPERIMENTAL
Intervention: Toborinone at 10 micrograms.kg‐1.min‐1
Number of subjects: 0
Study 9251504 — intervention group
Group type: EXPERIMENTAL
Intervention: Toborinone at 15 micrograms.kg‐1.min‐1
Number of subjects: 0
Study 8465408 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg
Number of subjects: 678
Study 8465408 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg
Number of subjects: 678
Study 8465408 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg for 3 days
Number of subjects: 678
Study 8465408 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg for 5 days
Number of subjects: 678
Study 8465408 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 678
Study 3516397 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 82
Study 3516397 — intervention group
Group type: EXPERIMENTAL
Intervention: BAFMi (carmustine, doxorubicin, 5-FU, and mitomycin)
Number of subjects: 82
Study 3516397 — intervention group
Group type: EXPERIMENTAL
Intervention: BAFMi
Number of subjects: 82
Study 30928954 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily
Number of subjects: 190
Study 30928954 — intervention group
Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times daily
Number of subjects: 190
Study 29384854 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE combined with MTX
Number of subjects: 100
Study 29384854 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE combined with MTX and 5-FU
Number of subjects: 100
Study 26694848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (light-moderate intensity aerobic and strength exercises, 3 sessions/week for 55-60 min from weeks 9-11 to 38-39)
Number of subjects: 241
Study 26694848 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 241
Study 25342184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium bicarbonate-buffered lidocaine
Number of subjects: 100
Study 25342184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthetic)
Number of subjects: 100
Study 25342184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 22956826 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered simultaneously with targets of varying contrast, with a single TMS pulse; specific dosage and duration not mentioned.
Number of subjects: 0
Study 22956826 — intervention group
Group type: COMPARATOR
Intervention: No adaptation (control condition)
Number of subjects: 0
Study 20157323 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 1256
Study 20157323 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 4 mg
Number of subjects: 1256
Study 20157323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1256
Study 17629631 — intervention group
Group type: EXPERIMENTAL
Intervention: tiagabine (20 mg/day)
Number of subjects: 141
Study 17629631 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 141
Study 16269957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose felodipine (extended release)
Number of subjects: 9800
Study 16269957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9800
Study 12505245 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 18000
Study 12505245 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker DHT
Number of subjects: 18000
Study 12505245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts as a gold standard
Number of subjects: 18000
Study 10562259 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 5674
Study 10562259 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic bivalirudin anticoagulation
Number of subjects: 5674
Study 8700313 — intervention group
Group type: COMPARATOR
Intervention: Postoperative flomoxef administration with saline containing no antibiotics for irrigation (Group A)
Number of subjects: 286
Study 8700313 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocol of flomoxef and saline containing gentamicin for irrigation (Group B)
Number of subjects: 286
Study 8700313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of the new protocol (Group C)
Number of subjects: 286
Study 2012420 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% NaCl solution prepared in hydroxyethylstarch (HES) solution (HS‐HES group)
Number of subjects: 30
Study 2012420 — intervention group
Group type: COMPARATOR
Intervention: 6% HES 200/0.5 solution (HES group)
Number of subjects: 30
Study 7026094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) given for 3 months at weekly intervals
Number of subjects: 27
Study 7026094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 7026094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 27
Study 29658430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1019
Study 29658430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 29658430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-L1 positive subgroup)
Number of subjects: 1019
Study 29658430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PD-L1 positive subgroup)
Number of subjects: 1019
Study 28893415 — intervention group
Group type: EXPERIMENTAL
Intervention: dCRT + cetuximab
Number of subjects: 258
Study 28893415 — intervention group
Group type: COMPARATOR
Intervention: dCRT
Number of subjects: 258
Study 26166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of fraction of exhaled nitric oxide (FENO) and sputum eosinophils
Number of subjects: 28
Study 26166613 — intervention group
Group type: COMPARATOR
Intervention: Clinical score based treatment (control group)
Number of subjects: 28
Study 24624781 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with fractionated dose (1 Gy + 1.5 Gy or 1 Gy + 2 Gy with 4‐hour intervals to a focal dose of 60 Gy)
Number of subjects: 257
Study 24624781 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (2 Gy 5 times a week)
Number of subjects: 257
Study 21695447 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 67
Study 21695447 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 67
Study 21695447 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 67
Study 21695447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 18435369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing before erosion (A)
Number of subjects: 10
Study 18435369 — intervention group
Group type: COMPARATOR
Intervention: Brushing after erosion (B)
Number of subjects: 10
Study 16931658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus followed by 1.75 mg x kg(‐1) x h(‐1) continuous infusion)
Number of subjects: 101
Study 16931658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 101
Study 16931658 — intervention group
Group type: COMPARATOR
Intervention: Heparin-protamine
Number of subjects: 101
Study 12075575 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED) and behaviour modification
Number of subjects: 19
Study 12075575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 9443697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 143
Study 9443697 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 143
Study 9443697 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 143
Study 7621842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg (maximum cumulative dose 0.3 mg)
Number of subjects: 15
Study 7621842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2229490 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin (retinoic acid)
Number of subjects: 30
Study 798468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide administered in a single daily dose
Number of subjects: 18
Study 798468 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide administered in divided daily doses
Number of subjects: 18
Study 6454632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6454632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 6454632 — intervention group
Group type: COMPARATOR
Intervention: Control (no secretory inhibitors)
Number of subjects: 0
Study 31471400 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery
Number of subjects: 110
Study 31471400 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 110
Study 31471400 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment
Number of subjects: 110
Study 31471400 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete tumor removal at surgery
Number of subjects: 110